Lilly Signs US$8.85 B Oncology and Immunology Partnership with Innovent Biologics

By Hitesh Udar

Pharma Deals Review: Vol 2026 Issue 2 (Table of Contents)

Published: 14 Feb-2026

DOI: 10.3833/pdr.v2026.i2.2999     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Lilly has entered into a global licensing and collaboration agreement with Innovent Biologics securing exclusive rights outside Greater China to develop and commercialise multiple oncology and immunology candidates...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details